Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

SIMPLE SUMMARY: More than 90% of patients with acute myeloid leukemia carry aberrant markers that can be detected using flow cytometry. Monitoring low levels of residual disease after treatment (measurable residual disease) is an important biomarker to assess the efficacy of treatment and can identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, Shin Yeu, Tan Si Yun, Melinda, Abdul Halim, Nurul Aidah, Christopher, Dheepa, Jen, Wei Ying, Gallardo, Christian, Tan Hwee Yim, Angeline, Woon, Yeow Kheong, Ng, Heng Joo, Ooi, Melissa, Wong, Gee Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332730/
https://www.ncbi.nlm.nih.gov/pubmed/35892834
http://dx.doi.org/10.3390/cancers14153576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332730/
https://www.ncbi.nlm.nih.gov/pubmed/35892834
http://dx.doi.org/10.3390/cancers14153576

Ejemplares similares